Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9045)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Apr 28, 2015 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Papamichael K, Vermeire S. Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease. World J Gastroenterol 2015; 21(16): 4773-4778 [PMID: 25944990 DOI: 10.3748/wjg.v21.i16.4773] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i16/4773.htm |
| Number | Citing Articles |
| 1 |
N. Mitrev, N. Vande Casteele, C. H. Seow, J. M. Andrews, S. J. Connor, G. T. Moore, M. Barclay, J. Begun, R. Bryant, W. Chan, C. Corte, S. Ghaly, D. A. Lemberg, V. Kariyawasam, P. Lewindon, J. Martin, R. Mountifield, G. Radford‐Smith, P. Slobodian, M. Sparrow, C. Toong, D. van Langenberg, M. G. Ward, R. W. Leong. Review article: consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics 2017; 46(11-12): 1037 doi: 10.1111/apt.14368
|
| 2 |
Leilei Zhu, Gil Y. Melmed. Treatment of Inflammatory Bowel Disease with Biologics. 2018; : 315 doi: 10.1007/978-3-319-60276-9_18
|
| 3 |
Joana Torres, Ray K. Boyapati, Nicholas A. Kennedy, Edouard Louis, Jean-Frédéric Colombel, Jack Satsangi. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology 2015; 149(7): 1716 doi: 10.1053/j.gastro.2015.08.055
|
| 4 |
Catarina Frias Gomes, Thomas P Chapman, Jack Satsangi. De-escalation of medical therapy in inflammatory bowel disease. Current Opinion in Pharmacology 2020; 55: 73 doi: 10.1016/j.coph.2020.09.014
|
| 5 |
Daniel J Wong, Eve M Roth, Joseph D Feuerstein, Vitaliy Y Poylin. Surgery in the age of biologics. Gastroenterology Report 2019; 7(2): 77 doi: 10.1093/gastro/goz004
|
| 6 |
Francisco Rodríguez-Moranta, Federico Argüelles-Arias, Joaquín Hinojosa del Val, Marisa Iborra Colomino, M. Dolores Martín-Arranz, Luis Menchén Viso, Fernando Muñoz Núñez, Elena Ricart Gómez, José Germán Sánchez-Hernández, Teresa Valdés-Delgado, Jordi Guardiola Capón, Manuel Barreiro-de Acosta, Míriam Mañosa Ciria, Yamile Zabana Abdo, Ana Gutiérrez Casbas. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis. Gastroenterología y Hepatología (English Edition) 2024; 47(5): 522 doi: 10.1016/j.gastre.2024.04.031
|
| 7 |
Rocío Sedano Muñoz, Rodrigo Quera Pino, Jaime Lubascher Correa, Gonzalo Pizarro Jofré, Daniela Simian Marín. Evaluation of de-escalation of anti-TNF-α therapy in inflammatory bowel disease. Gastroenterología y Hepatología (English Edition) 2019; 42(2): 133 doi: 10.1016/j.gastre.2019.02.013
|
| 8 |
Casper Steenholdt, Klaus Bendtzen, Jørn Brynskov, Mark A. Ainsworth. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. Inflammatory Bowel Diseases 2016; 22(8): 1999 doi: 10.1097/MIB.0000000000000772
|
| 9 |
Hansol Kim, Yoon Zi Kim, Seon Young Kim, Yon Ho Choe, Mi Jin Kim. Risk factors affecting relapse after discontinuation of biologics in children with Crohn's disease who maintained deep remission. Frontiers in Pediatrics 2024; 12 doi: 10.3389/fped.2024.1479619
|
| 10 |
Ben Kang, So Yoon Choi, Young Ok Choi, Min-ji Kim, Kyunga Kim, Ji-Hyuk Lee, Yon Ho Choe. Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn’s Disease Patients Treated With Combined Immunosuppressive Therapy. Journal of Crohn's and Colitis 2018; 12(6): 644 doi: 10.1093/ecco-jcc/jjy021
|
| 11 |
JG Sanchez-Hernandez, N Rebollo, F Munoz, A Martin-Suarez, MV Calvo. Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 2019; 56(1): 28 doi: 10.1177/0004563218782286
|
| 12 |
Thomas P Chapman, Catarina Frias Gomes, Edouard Louis, Jean-Frédéric Colombel, Jack Satsangi. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. The Lancet Gastroenterology & Hepatology 2020; 5(1): 63 doi: 10.1016/S2468-1253(19)30186-4
|
| 13 |
Francisco Rodríguez-Moranta, Federico Argüelles-Arias, Joaquín Hinojosa del Val, Marisa Iborra Colomino, M. Dolores Martín-Arranz, Luis Menchén Viso, Fernando Muñoz Núñez, Elena Ricart Gómez, José Germán Sánchez-Hernández, Teresa Valdés-Delgado, Jordi Guardiola Capón, Manuel Barreiro-de Acosta, Míriam Mañosa Ciria, Yamile Zabana Abdo, Ana Gutiérrez Casbas. Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Gastroenterología y Hepatología 2024; 47(5): 522 doi: 10.1016/j.gastrohep.2024.01.007
|
| 14 |
Hang Hock Shim, Cynthia H. Seow. Treatment of Inflammatory Bowel Disease with Biologics. 2018; : 141 doi: 10.1007/978-3-319-60276-9_10
|
| 15 |
Steven J. Bots, Sabine Kuin, Cyriel Y. Ponsioen, Krisztina B. Gecse, Marjolijn Duijvestein, Geert R. D’Haens, Mark Löwenberg. Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy. Scandinavian Journal of Gastroenterology 2019; 54(3): 281 doi: 10.1080/00365521.2019.1582693
|
| 16 |
Samuel O Adegbola, Kapil Sahnan, Charlene Twum-Barima, Nusrat Iqbal, Lillian Reza, Phillip Lung, Janindra Warusavitarne, Phil Tozer, Ailsa Hart. Current review of the management of fistulising perianal Crohn’s disease. Frontline Gastroenterology 2021; 12(6): 515 doi: 10.1136/flgastro-2020-101489
|
| 17 |
Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, Minoru Matsuura, Katsuyoshi Matsuoka, Taku Kobayashi, Masayuki Saruta, Fumihito Hirai, Keisuke Hata, Sakiko Hiraoka, Motohiro Esaki, Ken Sugimoto, Toshimitsu Fuji, Kenji Watanabe, Shiro Nakamura, Nagamu Inoue, Toshiyuki Itoh, Makoto Naganuma, Tadakazu Hisamatsu, Mamoru Watanabe, Hiroto Miwa, Nobuyuki Enomoto, Tooru Shimosegawa, Kazuhiko Koike. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. Journal of Gastroenterology 2021; 56(6): 489 doi: 10.1007/s00535-021-01784-1
|
| 18 |
Nurulamin M Noor, Paula Sousa, Dominik Bettenworth, Fernando Gomollón, Triana Lobaton, Peter Bossuyt, Maria Jose Casanova, Nik S Ding, Gabriele Dragoni, Federica Furfaro, Patrick F van Rheenen, Maria Chaparro, Javier P Gisbert, Edouard Louis, Konstantinos Papamichail. ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease. Journal of Crohn's and Colitis 2023; 17(7): 1031 doi: 10.1093/ecco-jcc/jjad001
|
| 19 |
Silvia Marquez-Megias, Ricardo Nalda-Molina, Javier Sanz-Valero, Patricio Más-Serrano, Marcos Diaz-Gonzalez, Maria Remedios Candela-Boix, Amelia Ramon-Lopez. Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review. Pharmaceutics 2022; 14(5): 1009 doi: 10.3390/pharmaceutics14051009
|
| 20 |
Konstantinos Papamichael, Adam S Cheifetz. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterology 2016; 7(4): 289 doi: 10.1136/flgastro-2016-100685
|
| 21 |
Laura E. Targownik, Aruni Tennakoon, Stella Leung, Lisa M. Lix, Zoann Nugent, Harminder Singh, Charles N. Bernstein. Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD. Inflammatory Bowel Diseases 2017; 23(3): 409 doi: 10.1097/MIB.0000000000001025
|
| 22 |
Catarina Frias Gomes, Jean-Frédéric Colombel, Joana Torres. De-escalation of Therapy in Inflammatory Bowel Disease. Current Gastroenterology Reports 2018; 20(8) doi: 10.1007/s11894-018-0643-8
|
| 23 |
J. Llaó, J.E. Naves, A. Ruiz-Cerulla, C. Romero, M. Mañosa, T. Lobatón, E. Cabré, J. Guardiola, E. Garcia-Planella, E. Domènech. Tratamiento de mantenimiento con azatioprina o infliximab en pacientes con colitis ulcerosa corticorrefractarios respondedores a las 3 dosis de inducción de infliximab. Enfermedad Inflamatoria Intestinal al Día 2017; 16(1): 15 doi: 10.1016/j.eii.2016.06.001
|
| 24 |
Marcello Cintolo, Giuseppe Costantino, Socrate Pallio, Walter Fries. Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World Journal of Gastrointestinal Pathophysiology 2016; 7(1): 1-16 doi: 10.4291/wjgp.v7.i1.1
|
| 25 |
Samuel O. Adegbola, Kapil Sahnan, Janindra Warusavitarne, Ailsa Hart, Philip Tozer. Anti-TNF Therapy in Crohn’s Disease. International Journal of Molecular Sciences 2018; 19(8): 2244 doi: 10.3390/ijms19082244
|
| 26 |
Feng Lv, Longbiao Yang, Jianxiu Wang, Zhixiang Chen, Qizhao Sun, Peiguo Zhang, Chentong Guan, Yanbin Liu. Inhibition of TNFR1 Attenuates LPS Induced Apoptosis and Inflammation in Human Nucleus Pulposus Cells by Regulating the NF-KB and MAPK Signalling Pathway. Neurochemical Research 2021; 46(6): 1390 doi: 10.1007/s11064-021-03278-1
|
| 27 |
Rocío Sedano Muñoz, Rodrigo Quera Pino, Jaime Lubascher Correa, Gonzalo Pizarro Jofré, Daniela Simian Marín. Evaluación del retiro progresivo y/o la suspensión de la terapia anti-TNF-α en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2019; 42(2): 133 doi: 10.1016/j.gastrohep.2018.10.010
|
| 28 |
Taku Kobayashi, Satoshi Motoya, Shiro Nakamura, Takayuki Yamamoto, Masakazu Nagahori, Shinji Tanaka, Tadakazu Hisamatsu, Fumihito Hirai, Hiroshi Nakase, Kenji Watanabe, Takayuki Matsumoto, Masanori Tanaka, Takayuki Abe, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi, Shingo Kato, Atsushi Maemoto, Minoru Matsuura, Ryosuke Sakemi, Makoto Sasaki, Tomoyuki Tsujikawa, Motohiro Esaki, Norimasa Fukata, Kazuya Kitamura, Sakiko Hiraoka, Ryota Hokari, Shunji Ishihara, Tsutomu Mizoshita, Yuji Naito, Fumio Omata, Masayuki Saruta, Takuya Yoshino. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. The Lancet Gastroenterology & Hepatology 2021; 6(6): 429 doi: 10.1016/S2468-1253(21)00062-5
|